Results 11 to 20 of about 3,384 (210)

A Hyperacute Presentation of Small Cell, Non-Nodal Mantle Cell Lymphoma [PDF]

Case Reports in Hematology
Mantle cell lymphoma (MCL) is an aggressive mature B-cell non-Hodgkin lymphoma. Patients often present with lymphadenopathy, early satiety, and B-symptoms. Presentation with hyperleukocytosis is rare.
Jodi Chiu, Mark Crowther
doaj   +2 more sources

Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study. [PDF]

Support Care Cancer
Cairo MS, Gallagher JR, Barnes Y, Drea E, Clark C, Carroll S.   +5 more
europepmc   +3 more sources

294 Evaluation of rasburicase use within the paediatric intensive care unit [PDF]

BMJ Paediatrics Open, 2021
Alex Christmas, Elizabeth Henderson, Edgar Brincat   +2 more
doaj   +2 more sources

Treatment with Rasburicase in Hospitalized Patients with Cardiorenal Syndrome: Old Treatment, New Scenario. [PDF]

Int J Mol Sci
Melero R, Torroba-Sanz B, Goicoechea M, Sousa-Casasnovas I, Barrio JM, García-Prieto AM, Rodriguez-Benitez P, García-González X, Sanjurjo-Sáez M.   +8 more
europepmc   +3 more sources

Unexpected Rasburicase-Induced Hemolysis in a Patient With Normal Glucose-6-Phosphate Dehydrogenase Activity. [PDF]

J Med Cases
Musleh Ud Din S, Shan K, Rehman TU, Ivanov S, Vargas-Madueno FM.   +4 more
europepmc   +3 more sources

Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels. [PDF]

Br J Clin Pharmacol
This review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Suarez-Kurtz G.
europepmc   +2 more sources

Survey of Anaphylaxis during Rasburicase Re-Administration in Patients with Hematological Malignancies Using a Japanese Claims Database

Current Oncology, 2022
Management of tumor lysis syndrome (TLS) associated with cancer chemotherapy for malignant tumors is important because of its potentially fatal course.
Shunsuke Kobayashi, Takeo Yasu, Manabu Akazawa   +2 more
doaj   +1 more source

Effectiveness and Safety of Allopurinol, Febuxostat, and Rasburicase in the Prevention of Tumor Lysis Syndrome: A Systematic Review and Network Meta-analysis

Asian Journal of Oncology, 2022
Although prevention is vital in managing tumor lysis syndrome (TLS), no study directly compares various regimens. This study compared the effectiveness and safety of urate-lowering agents in preventing TLS.
Ella Mae I. Masamayor, John Jefferson V. Besa, Carol Stephanie C. Tan-Lim, A. Nico Nahar I. Pajes, Lia M. Palileo-Villanueva   +4 more
doaj   +1 more source

Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study

Drugs in R&D, 2023
Introduction Despite rasburicase's proven efficiency in Caucasians, Japanese, and Koreans, studies evaluating the safety and effectiveness of rasburicase in Chinese pediatric patients with non-Hodgkin’s lymphoma (NHL) and acute leukemia (AL) in ...
Tianyou Wang, Xiaofan Zhu, Yumei Chen, Shuhong Shen, Yongmin Tang, Jingying Zhang, Yingyi He, Hui Zhang, Ju Gao, Jianpei Fang, Rong Liu, Xiaoyan Wu, Jinchuan Sun, Minlu Zhang   +13 more
doaj   +1 more source

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects. [PDF]

Clin Pharmacol Ther
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Bernsen EC, Verwiel ETP, van der Lee M, Swen JJ, Santoso M, Brigitha LJ, Admiraal R, Tops BBJ, Huitema ADR, Kemmeren P, Hehir-Kwa JY, Hanff LM, Diekstra MHM.   +12 more
europepmc   +2 more sources